Bladder Cancer Coverage from Every Angle

Simon J. Crabb, PhD, MBBS, on Rucaparib Following Chemotherapy for Urothelial Carcinoma: Update From the ATLANTIS Trial

Posted: Thursday, March 31, 2022

Simon J. Crabb, PhD, MBBS, of the Southampton Experimental Cancer Medicine Centre, discusses study results on the PARP inhibitor rucaparib, already approved in other settings, and what the findings could suggest for the treatment of certain biomarker-selected patients with metastatic urothelial cancer after they have received chemotherapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.